申请人:Rigel Pharmaceuticals, Inc.
公开号:US07557210B2
公开(公告)日:2009-07-07
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
本发明提供了抑制IgE和/或IgG受体信号级联引导化学介质释放的2,4-嘧啶二胺化合物,以及合成这些化合物的中间体和方法,并在多种情况下使用这些化合物的方法,包括在通过去颗粒化和其他通过激活IgE和/或IgG受体信号级联引起的化学介质释放所表征、引起或与之相关的疾病的治疗和预防中使用这些化合物的方法。